FDA recently approved
Moderna and
Pfizer/BioNTech's updated
Covid-19 vaccines intending to effectively tackle the
Omicron variant. This marked a crucial step against the elusive COVID virus, however,
BioNTech along with Pfizer encountered hurdles in their attempt to develop a
combined flu-Covid vaccine. Their combined vaccine had not achieved a key objective of the phase 3 trial causing the stocks to underperform. On another front, BioNTech initiated
clinical trials for a potential
lung cancer mRNA vaccine. An unfortunate setback came for
BioNTech-MediLink ADC trial as there were reported fatalities, however, it was later allowed to resume at lower doses by FDA. The regulatory body also approved BioNTech’s Updated COVID-19 Vaccine. BioNTech also secured $145M to enhance mRNA Vaccine capabilities in Africa. A patent dispute over the COVID shot technology emerged between
GlaxoSmithKline and Pfizer/BioNTech, while
Moderna seemed to have an early victory in Europe.
BioNTech faced a significant loss and continued disappointments in Covid vaccine sales, market slide and royalty disputes. Despite disappointments in fourth-quarter financials, the oncology shift of BioNTech outlined a promising scenario for the vaccine maker.
BIONTECH News Analytics from Tue, 19 Dec 2023 08:00:00 GMT to Sun, 25 Aug 2024 17:32:10 GMT -
Rating -5
- Innovation 7
- Information 8
- Rumor -3
